10:48 AM EST - Tetra Bio-Pharma Inc. : Announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug (delta-9-tetrahydrocannabinol 9.5% and cannabidiol 2.5%) for the treatment of complex regional pain syndrome (CRPS). The Orphan Drug Designation was granted for the active moiety of the drug PPP001 and not the formulation. Tetra Bio-Pharma Inc.
shares V.TBP are trading up $0.08 at $1.05.
